New hope for rare cholesterol disease: drug may shrink artery plaque
NCT ID NCT07447648
First seen Mar 06, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study looks at whether adding the drug evinacumab to standard cholesterol treatment can reduce or slow the buildup of plaque in the arteries of people with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. About 52 participants will get either evinacumab plus standard care or standard care alone, and their artery plaque will be measured with a special CT scan over 18-24 months. The goal is to see if this stronger treatment can lower the risk of heart disease in these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam University Medical Center, Amsterdam UMC, locatie AMC
RECRUITINGAmsterdam, Netherlands
Contact Email: •••••@•••••
Contact
-
Centro per le Malattie Rare del Metabolismo dei Lipidi, Unità di Medicina Interna e Malattie Metaboliche, Dipartimento di Medicina Traslazionale e di Precisione Sapienza, Università di Roma
RECRUITINGRoma, Italy
Contact Email: •••••@•••••
Contact
-
DAI di Medicina Clinica, Centro di Riferimento Regionale di Lipidologia e Dislipidemie, AOU Federico II di Napoli
RECRUITINGNaples, Italy
Contact Email: •••••@•••••
Contact
-
Dipartimento Scienze-Cardiovascolari, AO "Sant'Anna e San Sebastiano" di Caserta
RECRUITINGCaserta, Italy
Contact Email: •••••@•••••
Contact
-
Ege University,Director of Lipid and Prevention Clinic, Department of Cardiology
RECRUITINGBornova, Turkey (Türkiye)
Contact Email: •••••@•••••
Contact
-
Erasmus University Medical Center, Dr. Molewaterplein 40
NOT_YET_RECRUITINGRotterdam, Netherlands
Contact Email: •••••@•••••
Contact
-
Malattie Aterotrombotiche, Azienda Ospedaliero Universitaria Careggi
RECRUITINGFlorence, Italy
Contact Email: •••••@•••••
Contact
-
Medicina Interna, Ospedale Molinette, AOU Città della Salute e della Scienza
NOT_YET_RECRUITINGTorino, Italy
Contact
-
Nefrologia e Emodialisi, Centro Aterosclerosi e Dislipidemie, Ospedale Bassini, ASST Nord Milano
RECRUITINGCinisello Balsamo, Italy
Contact Email: •••••@•••••
Contact
-
U.O. Astanteria/MCAU AOU, Policlinico "Paolo Giaccone" di Palermo
RECRUITINGPalermo, Italy
Contact Email: •••••@•••••
Contact
-
U.O.C. di Medicina Interna, P.O. Nesima, ARNAS Garibaldi
NOT_YET_RECRUITINGCatania, Italy
Contact Email: •••••@•••••
Contact
-
UOC Clinica Medica I, AOU di Padova
NOT_YET_RECRUITINGPadova, Italy
Contact Email: •••••@•••••
Contact
-
Unité de Lipidologie et Prévention Cardiovasculaire, Centre de Compétence Dyslipidémies Rares (CEDRA), Service de Nutrition, Hôpital Pitié-Salpétriêre
NOT_YET_RECRUITINGParis, France
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.